Cite

HARVARD Citation

    , . et al. (2022). Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet. 10 (10), pp. 972-984. [Online]. 
  
Back to record